KYMR [NASD]
Kymera Therapeutics, Inc.
Index- P/E- EPS (ttm)-2.48 Insider Own1.20% Shs Outstand51.65M Perf Week-11.89%
Market Cap746.29M Forward P/E- EPS next Y-3.25 Insider Trans- Shs Float47.55M Perf Month-59.72%
Income-123.80M PEG- EPS next Q-0.71 Inst Own85.90% Short Float7.28% Perf Quarter-61.22%
Sales63.80M P/S11.70 EPS this Y-70.00% Inst Trans1.07% Short Ratio5.96 Perf Half Y-76.21%
Book/sh8.30 P/B1.79 EPS next Y-25.60% ROA-22.10% Target Price68.25 Perf Year-65.53%
Cash/sh8.40 P/C1.77 EPS next 5Y-14.90% ROE-30.40% 52W Range14.76 - 69.12 Perf YTD-76.55%
Dividend- P/FCF- EPS past 5Y- ROI-21.80% 52W High-78.48% Beta-
Dividend %- Quick Ratio4.90 Sales past 5Y- Gross Margin- 52W Low0.78% ATR2.33
Employees143 Current Ratio4.90 Sales Q/Q-48.70% Oper. Margin- RSI (14)22.39 Volatility8.10% 10.64%
OptionableYes Debt/Eq0.00 EPS Q/Q-142.50% Profit Margin- Rel Volume1.04 Prev Close14.89
ShortableYes LT Debt/Eq0.00 EarningsMay 03 BMO Payout- Avg Volume580.75K Price14.88
Recom1.90 SMA20-36.34% SMA50-54.72% SMA200-69.41% Volume64,104 Change-0.10%
Apr-28-22Initiated Credit Suisse Outperform $63
Mar-10-22Initiated JP Morgan Neutral $44
Feb-10-22Initiated Wells Fargo Overweight $62
Sep-30-21Initiated Stifel Buy $80
Sep-30-21Initiated B. Riley Securities Neutral $67
Sep-10-21Downgrade BofA Securities Buy → Neutral $65 → $80
May-21-21Initiated UBS Buy $80
Apr-14-21Initiated Berenberg Buy
Dec-04-20Initiated H.C. Wainwright Buy $85
Sep-15-20Initiated Morgan Stanley Equal-Weight $27
Sep-15-20Initiated Guggenheim Buy $42
Sep-15-20Initiated Cowen Outperform
Sep-15-20Initiated BofA Securities Neutral $35
May-20-22 07:30AM  
May-10-22 08:26AM  
May-05-22 08:00AM  
May-04-22 09:31AM  
May-03-22 02:18PM  
08:15AM  
07:00AM  
Apr-19-22 08:00AM  
Apr-08-22 01:02PM  
Mar-02-22 07:00AM  
Feb-24-22 10:15AM  
07:00AM  
Feb-20-22 12:47AM  
Feb-17-22 05:15PM  
Feb-07-22 07:55AM  
Jan-25-22 08:00AM  
Jan-18-22 08:00AM  
Jan-12-22 12:42PM  
Jan-10-22 07:00AM  
Jan-04-22 08:00AM  
Dec-22-21 11:11AM  
Dec-16-21 07:00AM  
Dec-13-21 08:00AM  
Dec-06-21 08:00AM  
Nov-30-21 08:00AM  
Nov-17-21 08:00AM  
Nov-12-21 07:00AM  
Nov-10-21 08:25AM  
07:00AM  
Nov-08-21 07:35AM  
Nov-04-21 08:00AM  
Nov-03-21 11:26AM  
Nov-01-21 08:00AM  
Oct-27-21 07:00AM  
04:50AM  
Oct-25-21 10:16AM  
Oct-20-21 08:00AM  
Oct-13-21 07:00AM  
Sep-16-21 01:43PM  
Sep-02-21 08:00AM  
Aug-08-21 03:37AM  
Aug-06-21 07:00AM  
Jul-29-21 07:00AM  
Jul-28-21 03:45PM  
Jul-12-21 08:00AM  
Jul-06-21 04:00PM  
Jun-30-21 09:45PM  
Jun-29-21 09:34AM  
08:56AM  
Jun-28-21 04:36PM  
08:55AM  
06:00AM  
Jun-21-21 04:00PM  
11:20AM  
08:00AM  
Jun-09-21 08:00AM  
Jun-02-21 04:00PM  
May-26-21 09:00AM  
May-19-21 01:36AM  
May-10-21 09:00AM  
May-08-21 04:06AM  
May-06-21 07:00AM  
May-05-21 07:00AM  
May-04-21 07:00AM  
May-03-21 04:00PM  
08:00AM  
Apr-19-21 07:30AM  
Apr-10-21 08:30AM  
Apr-09-21 07:30AM  
Mar-16-21 04:01PM  
Mar-11-21 07:00AM  
Mar-02-21 07:00AM  
Feb-25-21 07:00AM  
Feb-04-21 07:00AM  
Feb-03-21 07:00AM  
Jan-12-21 07:00AM  
Jan-05-21 04:01PM  
Dec-19-20 07:24PM  
Dec-16-20 07:00AM  
Dec-07-20 10:00AM  
Nov-26-20 12:22AM  
Nov-23-20 08:00AM  
Nov-21-20 03:15AM  
Nov-11-20 08:00AM  
Nov-05-20 07:00AM  
Nov-04-20 10:01AM  
Oct-12-20 07:00AM  
04:19AM  
Oct-09-20 07:00AM  
Sep-14-20 07:00AM  
Sep-09-20 07:00AM  
Aug-27-20 07:00AM  
Aug-25-20 04:01PM  
Aug-20-20 08:36PM  
Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis, and rheumatoid arthritis; IRAKIMiD program to treat MYD88-mutated diffuse large B cell lymphoma; and STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases. The company was founded in 2015 and is headquartered in Watertown, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
BVF PARTNERS L P/ILDirectorMay 06Buy19.25100,0001,925,5002,030,977May 09 07:20 PM
BVF PARTNERS L P/ILDirectorMay 05Buy19.60150,0002,939,8651,975,767May 09 07:20 PM
Gollob JaredChief Medical OfficerMay 04Option Exercise1.6920,00033,74057,257May 04 09:02 AM
Mainolfi NelloChief Executive OfficerMay 03Option Exercise2.0820,00041,600502,199May 03 07:27 PM
Jacobs Bruce N.Chief Financial OfficerMay 03Option Exercise2.0820,00041,60060,814May 03 07:26 PM
BVF PARTNERS L P/ILDirectorJan 31Buy40.7034,4081,400,4061,900,272Jan 31 07:44 PM
BVF PARTNERS L P/ILDirectorJan 27Buy38.3395,9013,676,0681,880,187Jan 31 07:44 PM
BVF PARTNERS L P/ILDirectorJan 24Buy37.76272,76710,300,6371,822,145Jan 26 07:43 PM
Mainolfi NelloChief Executive OfficerJan 14Option Exercise2.0810,00020,800482,199Jan 14 05:30 PM
Jacobs Bruce N.Chief Financial OfficerJan 14Option Exercise2.0810,00020,80027,514Jan 14 05:15 PM
Mainolfi NelloChief Executive OfficerJan 12Option Exercise2.088,61217,913480,811Jan 12 07:30 PM
Jacobs Bruce N.Chief Financial OfficerJan 12Option Exercise2.0815,00031,20032,514Jan 14 05:01 PM
Jacobs Bruce N.Chief Financial OfficerJan 12Sale51.8515,000777,68417,514Jan 14 05:01 PM
Mainolfi NelloChief Executive OfficerJan 12Sale52.088,612448,551472,199Jan 12 07:30 PM
Mainolfi NelloChief Executive OfficerJan 11Option Exercise2.0816,92335,200489,122Jan 12 07:30 PM
Mainolfi NelloChief Executive OfficerJan 11Sale54.0016,923913,795472,199Jan 12 07:30 PM
Mainolfi NelloChief Executive OfficerJan 10Option Exercise2.0822,46546,727494,664Jan 12 07:30 PM
Mainolfi NelloChief Executive OfficerJan 10Sale53.2622,4651,196,397472,199Jan 12 07:30 PM
Mainolfi NelloChief Executive OfficerDec 16Option Exercise2.088,00016,640472,199Dec 16 04:49 PM
Jacobs Bruce N.Chief Financial OfficerDec 03Option Exercise2.0810,00020,80027,514Dec 03 06:43 PM
Jacobs Bruce N.Chief Financial OfficerDec 03Sale53.5610,000535,63717,514Dec 03 06:43 PM
Jacobs Bruce N.Chief Financial OfficerNov 23Option Exercise2.0810,00020,80017,256Nov 23 04:59 PM
Gollob JaredChief Medical OfficerNov 02Option Exercise2.0814,99631,19239,653Nov 02 06:45 PM
Gollob JaredChief Medical OfficerNov 02Sale63.2214,996948,06324,657Nov 02 06:45 PM
Gollob JaredChief Medical OfficerNov 01Option Exercise1.4524,60735,78367,154Nov 02 06:45 PM
Gollob JaredChief Medical OfficerNov 01Sale61.7842,4972,625,59524,657Nov 02 06:45 PM
Mainolfi NelloChief Executive OfficerOct 11Option Exercise2.086,45613,428470,655Oct 12 04:30 PM
Mainolfi NelloChief Executive OfficerOct 11Sale53.686,456346,590464,199Oct 12 04:30 PM
Mainolfi NelloChief Executive OfficerOct 08Option Exercise2.0841,54486,412505,743Oct 12 04:30 PM
Mainolfi NelloChief Executive OfficerOct 08Sale56.7641,5442,357,946464,199Oct 12 04:30 PM
Jacobs Bruce N.Chief Financial OfficerSep 03Sale60.1210,000601,1807,256Sep 03 05:57 PM
Chesworth RichardChief Scientific OfficerAug 27Option Exercise20.0033,779675,58033,779Aug 27 04:55 PM
Chesworth RichardChief Scientific OfficerAug 27Sale60.1233,7792,030,8640Aug 27 04:55 PM
Mainolfi NelloChief Executive OfficerAug 19Option Exercise2.0812,00024,960464,199Aug 19 04:30 PM
Chesworth RichardChief Scientific OfficerAug 17Option Exercise20.0054,0001,080,00054,000Aug 19 04:30 PM
Chesworth RichardChief Scientific OfficerAug 17Sale50.3754,0002,720,1820Aug 19 04:30 PM
Booth BruceDirectorAug 11Sale61.00242,13314,770,1130Aug 12 10:43 AM
ATLAS VENTURE ASSOCIATES X, L.10% OwnerAug 11Sale61.00242,13314,770,1130Aug 12 10:42 AM
Mainolfi NelloChief Executive OfficerAug 04Option Exercise2.081,0372,157453,236Aug 05 04:14 PM
Mainolfi NelloChief Executive OfficerAug 04Sale60.031,03762,253452,199Aug 05 04:14 PM
Mainolfi NelloChief Executive OfficerAug 03Option Exercise2.085,66911,792457,868Aug 05 04:14 PM
Mainolfi NelloChief Executive OfficerAug 03Sale60.075,669340,533452,199Aug 05 04:14 PM
Mainolfi NelloChief Executive OfficerAug 02Option Exercise2.0823,45648,788475,655Aug 02 05:53 PM
Mainolfi NelloChief Executive OfficerAug 02Sale60.3023,4561,414,404452,199Aug 02 05:53 PM
Mainolfi NelloChief Executive OfficerJul 30Option Exercise2.086,27913,060458,478Aug 02 05:53 PM
Mainolfi NelloChief Executive OfficerJul 30Sale60.076,279377,167452,199Aug 02 05:53 PM
Mainolfi NelloChief Executive OfficerJul 29Option Exercise2.086801,414452,879Aug 02 05:53 PM
Mainolfi NelloChief Executive OfficerJul 29Sale60.0068040,800452,199Aug 02 05:53 PM
Mainolfi NelloChief Executive OfficerJul 28Option Exercise2.083,8648,037456,063Jul 28 04:57 PM
Mainolfi NelloChief Executive OfficerJul 28Sale60.153,864232,410452,199Jul 28 04:57 PM
Mainolfi NelloChief Executive OfficerJul 26Option Exercise2.089,01518,751461,214Jul 28 04:57 PM
Mainolfi NelloChief Executive OfficerJul 26Sale60.159,015542,237452,199Jul 28 04:57 PM
Mainolfi NelloChief Executive OfficerJul 08Option Exercise2.0848,00099,840500,199Jul 09 04:30 PM
Mainolfi NelloChief Executive OfficerJul 08Sale49.7048,0002,385,628452,199Jul 09 04:30 PM
BVF PARTNERS L P/ILDirectorJul 01Buy47.00544,16625,575,8021,664,104Jul 06 06:40 PM
Mainolfi NelloChief Executive OfficerJun 14Option Exercise2.0840,00083,200452,199Jun 14 05:57 PM
Mainolfi NelloChief Executive OfficerJun 10Option Exercise2.0823,00947,859435,208Jun 11 04:15 PM
Mainolfi NelloChief Executive OfficerJun 10Sale51.3823,0091,182,106412,199Jun 11 04:15 PM
Mainolfi NelloChief Executive OfficerJun 09Option Exercise2.085,75211,964417,951Jun 09 05:54 PM
Mainolfi NelloChief Executive OfficerJun 09Sale50.025,752287,721412,199Jun 09 05:54 PM
Mainolfi NelloChief Executive OfficerJun 08Option Exercise2.08270562412,469Jun 09 05:54 PM
Mainolfi NelloChief Executive OfficerJun 08Sale50.0027013,500412,199Jun 09 05:54 PM
Mainolfi NelloChief Executive OfficerJun 07Option Exercise2.0812,72426,466424,923Jun 09 05:54 PM
Mainolfi NelloChief Executive OfficerJun 07Sale50.1412,724638,040412,199Jun 09 05:54 PM
Jacobs Bruce N.Chief Financial OfficerJun 03Option Exercise2.0810,00020,80017,256Jun 04 04:16 PM
Jacobs Bruce N.Chief Financial OfficerJun 03Sale46.8710,000468,6957,256Jun 04 04:16 PM